Robert A Wise

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6392675/publications.pdf

Version: 2024-02-01

412 papers

31,263 citations

4370 86 h-index 162 g-index

427 all docs

427 docs citations

times ranked

427

22116 citing authors

#	Article	IF	Citations
1	A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema. New England Journal of Medicine, 2003, 348, 2059-2073.	13.9	1,842
2	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. New England Journal of Medicine, 2006, 354, 2655-2666.	13.9	1,421
3	Long-Term Effects of Budesonide or Nedocromil in Children with Asthma. New England Journal of Medicine, 2000, 343, 1054-1063.	13.9	1,376
4	The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. Annals of Internal Medicine, 2005, 142, 233.	2.0	1,051
5	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680.	13.9	823
6	Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2000, 343, 1902-1909.	13.9	785
7	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	5 . 2	754
8	Patients at High Risk of Death after Lung-Volume–Reduction Surgery. New England Journal of Medicine, 2001, 345, 1075-1083.	13.9	612
9	Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. New England Journal of Medicine, 2016, 374, 1842-1852.	13.9	456
10	Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax, 2007, 62, 411-415.	2.7	426
11	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1026-1034.	2.5	411
12	Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1326-1334.	2.5	392
13	Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. New England Journal of Medicine, 2009, 360, 1487-1499.	13.9	357
14	Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis. Annals of Internal Medicine, 2000, 132, 947.	2.0	335
15	Six-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1522-1527.	2.5	331
16	A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. New England Journal of Medicine, 2016, 375, 1617-1627.	13.9	327
17	Tiotropium Respimat Inhaler and the Risk of Death in COPD. New England Journal of Medicine, 2013, 369, 1491-1501.	13.9	318
18	Metered-Dose Inhaler Adherence in a Clinical Trial. The American Review of Respiratory Disease, 1992, 146, 1559-1564.	2.9	303

#	Article	IF	CITATIONS
19	Sex Differences in Severe Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 243-252.	2.5	301
20	Association between Functional Small Airway Disease and FEV ₁ Decline in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 178-184.	2.5	292
21	Measuring Adherence to Asthma Medication Regimens. American Journal of Respiratory and Critical Care Medicine, 1994, 149, S69-S76.	2.5	288
22	Acquired Methemoglobinemia. Medicine (United States), 2004, 83, 265-273.	0.4	284
23	Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. Science Translational Medicine, 2011, 3, 78ra32.	5.8	271
24	The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation. The American Review of Respiratory Disease, 1992, 145, 301-310.	2.9	258
25	Asthma morbidity during pregnancy can be predicted by severity classification. Journal of Allergy and Clinical Immunology, 2003, 112, 283-288.	1.5	252
26	Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 125-129.	0.7	249
27	Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 379-385.	2.5	225
28	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 619-626.	5.2	219
29	The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 428-433.	2.5	218
30	Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2012, 307, 373-380.	3.8	214
31	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 956-967.	5.2	211
32	Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 1168-1178.	6.7	201
33	The relationship of asthma medication use to perinatal outcomes. Journal of Allergy and Clinical Immunology, 2004, 113, 1040-1045.	1.5	189
34	Maternal Vitamin A Supplementation and Lung Function in Offspring. New England Journal of Medicine, 2010, 362, 1784-1794.	13.9	186
35	Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. New England Journal of Medicine, 2007, 356, 2027-2039.	13.9	184
36	Asthma During Pregnancy. Obstetrics and Gynecology, 2004, 103, 5-12.	1.2	173

#	Article	IF	Citations
37	Respiratory Physiologic Changes in Pregnancy. Immunology and Allergy Clinics of North America, 2006, 26, 1-12.	0.7	171
38	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
39	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respiratory Medicine,the, 2019, 7, 745-756.	5.2	159
40	Mortality in COPD: Causes, Risk Factors, and Prevention. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 375-382.	0.7	158
41	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322.	2.5	157
42	Telomerase mutations in smokers with severe emphysema. Journal of Clinical Investigation, 2015, 125, 563-570.	3.9	152
43	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	2.5	151
44	Feasibility of Retinoids for the Treatment of Emphysema Study. Chest, 2006, 130, 1334-1345.	0.4	150
45	Heightened Endoplasmic Reticulum Stress in the Lungs of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1196-1207.	2.5	150
46	Physician and patient perceptions in COPD: The COPD Resource Network Needs Assessment Survey. American Journal of Medicine, 2005, 118, 1415.e9-1415.e17.	0.6	144
47	Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 575-591.	0.8	144
48	Effect of Obesity on Clinical Presentation and Response to Treatment in Asthma. Journal of Asthma, 2006, 43, 553-558.	0.9	142
49	The Value of Forced Expiratory Volume in 1 Second Decline in the Assessment of Chronic Obstructive Pulmonary Disease Progression. American Journal of Medicine, 2006, 119, 4-11.	0.6	142
50	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	3.1	138
51	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 2037-2047.e10.	1.5	138
52	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1397-1405.	2.5	132
53	Association between Household Air Pollution Exposure and Chronic Obstructive Pulmonary Disease Outcomes in 13 Low- and Middle-Income Country Settings. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 611-620.	2.5	129
54	The effect of gender on the relationship between body fat distribution and lung function. Journal of Clinical Epidemiology, 2001, 54, 399-406.	2.4	126

#	Article	IF	CITATIONS
55	Allergic Rhinitis and Sinusitis in Asthma. Chest, 2006, 130, 429-435.	0.4	123
56	Oxygen Therapy in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2008, 5, 513-518.	3.5	123
57	Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1413-1419.	2.5	121
58	Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. Journal of Allergy and Clinical Immunology, 2012, 129, 112-118.	1.5	119
59	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. Journal of Clinical Investigation, 2011, 121, 4289-4302.	3.9	116
60	African-American Race and Antibodies to Topoisomerase I Are Associated With Increased Severity of Scleroderma Lung Disease. Chest, 1998, 114, 801-807.	0.4	115
61	Spirometry is related to perinatal outcomes in pregnant women with asthma. American Journal of Obstetrics and Gynecology, 2006, 194, 120-126.	0.7	115
62	Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 491-499.	2.5	114
63	Age and Risk of Pulmonary Arterial Hypertension in Scleroderma*. Chest, 2003, 124, 2098-2104.	0.4	113
64	Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest, 2017, 151, 68-77.	0.4	113
65	Serum Vitamin Levels and the Risk of Asthma in Children. American Journal of Epidemiology, 2004, 159, 351-357.	1.6	112
66	The effect of HIV infection on longitudinal lung function decline among IDUs. Aids, 2013, 27, 1303-1311.	1.0	112
67	Angiotensin receptor blockade attenuates cigarette smoke–induced lung injury and rescues lung architecture in mice. Journal of Clinical Investigation, 2012, 122, 229-240.	3.9	110
68	Gene Expression in Bronchoalveolar Lavage Cells from Scleroderma Patients. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 549-557.	1.4	109
69	Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis and Rheumatism, 2003, 48, 2262-2274.	6.7	107
70	Changes in Smoking Status Affect Women More than Men: Results of the Lung Health Study. American Journal of Epidemiology, 2003, 157, 973-979.	1.6	107
71	Unpredictability of Deception in Compliance With Physician-Prescribed Bronchodilator Inhaler Use in a Clinical Trial. Chest, 2000, 118, 290-295.	0.4	104
72	Body Mass Index and the Risk of COPD. Chest, 2002, 121, 370-376.	0.4	103

#	Article	IF	CITATIONS
73	Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1302-1309.	2.5	102
74	Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. American Journal of Obstetrics and Gynecology, 2004, 190, 737-744.	0.7	102
75	Effect of urbanisation on asthma, allergy and airways inflammation in a developing country setting. Thorax, 2011, 66, 1051-1057.	2.7	101
76	Racial Difference in Lung Function in African-American and White Children: Effect of Anthropometric, Socioeconomic, Nutritional, and Environmental Factors. American Journal of Epidemiology, 2004, 160, 893-900.	1.6	100
77	Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma. JAMA - Journal of the American Medical Association, 2017, 317, 1027.	3.8	96
78	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax, 2018, 73, 414-421.	2.7	96
79	Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers. Journal of Allergy and Clinical Immunology, 2009, 124, 436-444.e8.	1.5	94
80	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. Journal of Allergy and Clinical Immunology, 2004, 113, 717-724.	1.5	93
81	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis and Rheumatism, 2007, 56, 1676-1684.	6.7	93
82	Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1187-1192.	2.5	93
83	Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. American Journal of Medicine, 1984, 77, 1027-1034.	0.6	92
84	Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE, 2016, 11, e0163716.	1.1	92
85	Paradoxical physical findings described by Kussmaul: pulsus paradoxus and Kussmaul's sign. Lancet, The, 2002, 359, 1940-1942.	6.3	91
86	Spirometric Predictors of Lung Function Decline and Mortality in Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1301-1306.	2.5	91
87	Effects of Multiple Attempts to Quit Smoking and Relapses to Smoking on Pulmonary Function. Journal of Clinical Epidemiology, 1998, 51, 1317-1326.	2.4	89
88	Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax, 2012, 67, 309-314.	2.7	86
89	American Thoracic Society/National Heart, Lung, and Blood Institute Asthma–Chronic Obstructive Pulmonary Disease Overlap Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 375-381.	2.5	86
90	Clinical Significance of Radiologic Characterizations in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 459-467.	0.7	85

#	Article	IF	CITATIONS
91	Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. Journal of Rheumatology, 2006, 33, 269-74.	1.0	82
92	Chronic exposure to biomass fuel is associated with increased carotid artery intima-media thickness and a higher prevalence of atherosclerotic plaque. Heart, 2013, 99, 984-991.	1.2	79
93	Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. Journal of Clinical Investigation, 2020, 130, 3750-3760.	3.9	78
94	Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1371.	3.8	75
95	Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2019, 16, 217-224.	1.5	7 5
96	Efficacy and tolerability of a selective ?2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis and Rheumatism, 2004, 50, 3994-4001.	6.7	74
97	Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Annals of the Rheumatic Diseases, 2007, 66, 1641-1647.	0.5	74
98	Physical Activity, Health Status and Risk of Hospitalization in Patients with Severe Chronic Obstructive Pulmonary Disease. Respiration, 2010, 80, 10-18.	1.2	73
99	Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. Journal of General Internal Medicine, 2017, 32, 1315-1322.	1.3	73
100	Trends in Compliance With Bronchodilator Inhaler Use Between Follow-up Visits in a Clinical Trial. Chest, 1996, 109, 963-968.	0.4	72
101	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72
102	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
103	Skewing of the CDS + T-cell repertoire in the lungs of patients with systemic sclerosis. Human Immunology, 1996, 48, 84-97.	1.2	71
104	Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. Respiratory Research, 2010, 11, 29.	1.4	71
105	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. Chest, 2014, 146, 941-950.	0.4	71
106	Association of Obesity With Pulmonary and Nonpulmonary Complications of Pregnancy in Asthmatic Women. Obstetrics and Gynecology, 2006, 108, 77-82.	1.2	70
107	Sleep Quality in Asthma: Results of a Large Prospective Clinical Trial. Journal of Asthma, 2008, 45, 183-189.	0.9	70
108	The health and social implications of household air pollution and respiratory diseases. Npj Primary Care Respiratory Medicine, 2019, 29, 12.	1.1	70

#	Article	IF	CITATIONS
109	Changing Smoking Patterns and Mortality from Chronic Obstructive Pulmonary Disease. Preventive Medicine, 1997, 26, 418-421.	1.6	69
110	Methacholine challenge test: Diagnostic characteristics in asthmatic patients receiving controller medications. Journal of Allergy and Clinical Immunology, 2012, 130, 69-75.e6.	1.5	69
111	Clinical and Demographic Predictors of Loss of Pulmonary Function in Systemic Sclerosis. Medicine (United States), 1984, 63, 221-231.	0.4	67
112	Association Between Expiratory Central Airway Collapse and Respiratory Outcomes Among Smokers. JAMA - Journal of the American Medical Association, 2016, 315, 498.	3.8	67
113	Does Age Impact the Obese Asthma Phenotype?. Chest, 2011, 140, 1524-1533.	0.4	66
114	The Effect of Smoking Intervention and an Inhaled Bronchodilator on Airways Reactivity in COPD*. Chest, 2003, 124, 449-458.	0.4	64
115	Effects of Asymptomatic Proximal and Distal Gastroesophageal Reflux on Asthma Severity. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 809-816.	2.5	61
116	Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respiratory Research, 2015, 16, 40.	1.4	61
117	Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension. Chest, 2015, 147, 188-197.	0.4	60
118	Relationship Between Daily Exposure to Biomass Fuel Smoke and Blood Pressure in High-Altitude Peru. Hypertension, 2015, 65, 1134-1140.	1.3	60
119	Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respiratory Research, 2015, 16, 115.	1.4	59
120	A Simplified Score to Quantify Comorbidity in COPD. PLoS ONE, 2014, 9, e114438.	1,1	58
121	Diffusing Capacity of Carbon Monoxide inÂAssessment of COPD. Chest, 2019, 156, 1111-1119.	0.4	58
122	Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine, 1984, 77, 451-456.	0.6	56
123	Adult asthma severity in individuals with a history of childhood asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 61-66.	1.5	56
124	Variability of Spirometry in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1106-1113.	2.5	56
125	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 294-302.	2.5	56
126	Dietary Intake of Soy Genistein is Associated with Lung Function in Patients with Asthma. Journal of Asthma, 2004, 41, 833-843.	0.9	55

#	Article	IF	CITATIONS
127	Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. European Heart Journal, 2011, 32, 1918-1925.	1.0	55
128	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	1.4	55
129	Measurement Variability in Single-Breath Diffusing Capacity of the Lung. Chest, 2003, 123, 1082-1089.	0.4	54
130	The IBV Valve Trial. Journal of Bronchology and Interventional Pulmonology, 2014, 21, 288-297.	0.8	53
131	Irreversible lung function deficits in young adults with a history of childhood asthma. Journal of Allergy and Clinical Immunology, 2005, 116, 1213-1219.	1.5	51
132	Exercise Testing in Severe Emphysema: Association with Quality of Life and Lung Function. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 117-124.	0.7	51
133	Criteria To Screen for Chronic Sinonasal Disease. Chest, 2009, 136, 1324-1332.	0.4	51
134	Accuracy of Death Certificates in COPD: Analysis from the TORCH Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 179-185.	0.7	51
135	The Complex Relationship of Serum Adiponectin to COPD Outcomes. Chest, 2012, 142, 893-899.	0.4	51
136	Airway Obstruction Is Common but Unsuspected in Patients Admitted to a General Medicine Service. Chest, 2004, 125, 106-111.	0.4	48
137	The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respiratory Research, 2013, 14, 40.	1.4	48
138	Validation and psychometric properties of the Asthma Control Questionnaire among children. Journal of Allergy and Clinical Immunology, 2014, 133, 91-97.e6.	1.5	48
139	Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 701-709.e5.	1.5	48
140	Field Tests of Exercise in COPD: The Six-Minute Walk Test and the Shuttle Walk Test. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2007, 4, 217-223.	0.7	47
141	Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children. Journal of Pediatrics, 2013, 163, 686-691.	0.9	47
142	Race, Lung Function, and Long-Term Mortality in the National Health and Nutrition Examination Survey III. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 723-724.	2.5	46
143	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 47-55.	2.5	46
144	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. Human Genetics, 2013, 132, 79-90.	1.8	45

#	Article	IF	CITATIONS
145	Continuous Oxygen Use in Nonhypoxemic Emphysema Patients Identifies a High-Risk Subset of Patients. Chest, 2008, 134, 497-506.	0.4	44
146	Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru. Journal of Allergy and Clinical Immunology, 2011, 127, 875-882.	1.5	44
147	Airway hyperresponsiveness in chronic obstructive pulmonary disease: AÂmarker of asthma-chronic obstructive pulmonary disease overlap syndrome?. Journal of Allergy and Clinical Immunology, 2016, 138, 1571-1579.e10.	1.5	44
148	Prevalence, Clinical Profile, Iron Status, and Subject-Specific Traits for Excessive Erythrocytosis in Andean Adults Living Permanently at 3,825 Meters Above Sea Level. Chest, 2014, 146, 1327-1336.	0.4	43
149	Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema. PLoS ONE, 2013, 8, e56352.	1.1	43
150	Extensive Surface Phenotyping of Alveolar Macrophages in Interstitial Lung Disease. Clinical Immunology, 2000, 94, 33-41.	1.4	42
151	Racial Differences in CT Phenotypes in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 20-27.	0.7	42
152	Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. Chest, 2013, 144, 490-497.	0.4	42
153	Activation-induced Cell Death Drives Profound Lung CD4 ⁺ T-Cell Depletion in HIV-associated Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 744-755.	2.5	42
154	HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 68-74.	0.9	42
155	Urbanisation but not biomass fuel smoke exposure is associated with asthma prevalence in four resource-limited settings. Thorax, 2016, 71, 154-160.	2.7	42
156	The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. International Journal of COPD, 2018, Volume 13, 1009-1019.	0.9	42
157	Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. Journal of Allergy and Clinical Immunology, 2012, 130, 1078-1084.	1.5	41
158	Effect of a Soy Isoflavone Supplement on Lung Function and Clinical Outcomes in Patients With Poorly Controlled Asthma. JAMA - Journal of the American Medical Association, 2015, 313, 2033.	3.8	41
159	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2019, 16, 826-835.	1.5	41
160	Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health: Results of the CLEAN AIR Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 421-430.	2.5	41
161	Prevalence of chronic respiratory disease in urban and rural Uganda. Bulletin of the World Health Organization, 2019, 97, 318-327.	1.5	41
162	Transforming Growth Factor- \hat{l}^2 Receptor-3 Is Associated with Pulmonary Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 324-331.	1.4	40

#	Article	IF	Citations
163	Transcriptional responses of neonatal mouse lung to hyperoxia by Nrf2 status. Cytokine, 2014, 65, 4-9.	1.4	40
164	Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. International Journal of COPD, 2017, Volume 12, 3391-3405.	0.9	40
165	Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2018, 320, 2335.	3.8	40
166	The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be aÂBetter Predictor of COPD Exacerbations Compared With the Classic Definition. Chest, 2019, 156, 685-695.	0.4	40
167	Comorbidities of COPD Have a Major Impact on Clinical Outcomes, Particularly in African Americans. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 105-114.	0.5	40
168	Eosinophil and T cell markers predict functional decline in COPD patients. Respiratory Research, 2009, 10, 113.	1.4	39
169	The Effect of Active and Passive Household Cigarette Smoke Exposure on Pregnant Women With Asthma. Chest, 2010, 137, 601-608.	0.4	38
170	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. Cmaj, 2016, 188, 1004-1011.	0.9	38
171	Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude. High Altitude Medicine and Biology, 2016, 17, 93-100.	0.5	38
172	Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. Journal of Allergy and Clinical Immunology, 2019, 143, 1598-1606.	1.5	38
173	The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 540-554.	2.5	38
174	A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. European Respiratory Journal, 2021, 57, 2003103.	3.1	38
175	The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1060-1066.	0.5	37
176	Single-Breath Diffusing Capacity of the Lung for Carbon Monoxide. Chest, 2003, 123, 1394-1400.	0.4	36
177	A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Annals of the Rheumatic Diseases, 2013, 72, 1962-1967.	0.5	36
178	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2016, 13, 1016-1025.	1.5	36
179	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. Chest, 2018, 153, 65-76.	0.4	36
180	Associations Among 25-Hydroxyvitamin DÂLevels, Lung Function, and Exacerbation Outcomes in COPD. Chest, 2020, 157, 856-865.	0.4	35

#	Article	IF	CITATIONS
181	Chronic intermittent hypoxia induces lung growth in adult mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L266-L273.	1.3	34
182	Obesity in children with poorly controlled asthma: Sex differences. Pediatric Pulmonology, 2013, 48, 847-856.	1.0	34
183	Measurement characteristics of the childhood Asthma-Control Test and a shortened, child-only version. Npj Primary Care Respiratory Medicine, 2016, 26, 16075.	1.1	34
184	Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches. Respiratory Medicine, 2016, 121, 59-66.	1.3	34
185	Selection of Spirometric Measurements in a Clinical Trial, the Lung Health Study. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 675-681.	2.5	33
186	Impaired Lung Homeostasis in Neonatal Mice Exposed to Cigarette Smoke. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 393-400.	1.4	33
187	Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulmonary Medicine, 2010, 10, 27.	0.8	33
188	Integrating Health Status and Survival Data. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 239-246.	2.5	32
189	Aquaporin 5 Polymorphisms and Rate of Lung Function Decline in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2010, 5, e14226.	1.1	32
190	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 808-816.	1.5	32
191	Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2018, 15, 926-934.	1.5	32
192	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals of the American Thoracic Society, 2018, 15, 710-717.	1.5	32
193	Reduction in mouse allergen exposure is associated with greater lung function growth. Journal of Allergy and Clinical Immunology, 2020, 145, 646-653.e1.	1.5	32
194	The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma. Journal of Allergy and Clinical Immunology, 2011, 127, 406-411.	1.5	31
195	Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. International Journal of COPD, 2011, 6, 89.	0.9	31
196	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Annals of the American Thoracic Society, 2019, 16, 200-208.	1.5	31
197	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Lowand Middle-Income Country Settings. JAMA - Journal of the American Medical Association, 2022, 327, 151.	3.8	31
198	Nicardipine in the treatment of raynaud's phenomenon. Arthritis and Rheumatism, 1987, 30, 281-286.	6.7	30

#	Article	IF	Citations
199	HIV and COPD: impact of risk behaviors and diseases on quality of life. Quality of Life Research, 2010, 19, 1295-1302.	1.5	30
200	Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease. Journal of Pain and Symptom Management, 2013, 46, 491-499.e4.	0.6	30
201	Biologic Mechanisms of Environmental Tobacco Smoke in Children with Poorly Controlled Asthma: Results from a Multicenter Clinical Trial. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 172-180.e2.	2.0	29
202	Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial. Annals of the American Thoracic Society, 2016, 13, 1940-1950.	1.5	29
203	The Relationship of Asthma-Specific Quality of Life During Pregnancy to Subsequent Asthma and Perinatal Morbidity. Journal of Asthma, 2010, 47, 46-50.	0.9	28
204	Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease. Chest, 2012, 142, 704-711.	0.4	28
205	Use of mobile devices and the internet for multimedia informed consent delivery and data entry in a pediatric asthma trial: Study design and rationale. Contemporary Clinical Trials, 2015, 42, 105-118.	0.8	28
206	Electronic cigarette use behaviors and motivations among smokers and non-smokers. BMC Public Health, 2017, 17, 686.	1.2	28
207	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	2.5	28
208	Lack of Long-term Adverse Adrenal Effects From Inhaled Triamcinolone. Chest, 2003, 124, 57-62.	0.4	27
209	The Peru Urban versus Rural Asthma (PURA) Study: methods and baseline quality control data from a cross-sectional investigation into the prevalence, severity, genetics, immunology and environmental factors affecting asthma in adolescence in Peru. BMJ Open, 2012, 2, e000421.	0.8	27
210	Optimizing the 6-Min Walk Test as a Measure of Exercise Capacity in COPD. Chest, 2012, 142, 1545-1552.	0.4	27
211	Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 226-234.	1.4	27
212	Serum Bilirubin and Disease Progression in Mild COPD. Chest, 2015, 148, 169-175.	0.4	27
213	Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. EBioMedicine, 2017, 19, 139-145.	2.7	27
214	Standardization of the Single-Breath Diffusing Capacity in a Multicenter Clinical Trial. Chest, 2007, 132, 1191-1197.	0.4	26
215	Lansoprazole Is Associated with Worsening Asthma Control in Children with the <i>CYP2C19</i> Poor Metabolizer Phenotype. Annals of the American Thoracic Society, 2015, 12, 878-885.	1.5	26
216	HIV Suppression Restores the Lung Mucosal CD4 ⁺ T-Cell Viral Immune Response and Resolves CD8 ⁺ T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2016, 214, 1520-1530.	1.9	26

#	Article	IF	CITATIONS
217	BMI but not central obesity predisposes to airway closure during bronchoconstriction. Respirology, 2019, 24, 543-550.	1.3	26
218	Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Research and Therapy, 2013, 15, R54.	1.6	25
219	Chronic Productive Cough is Associated with Death in Smokers with Early COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 451-458.	0.7	25
220	Do Patients Hospitalized With COPD Have Airflow Obstruction?. Chest, 2017, 151, 1263-1271.	0.4	25
221	Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS ONE, 2018, 13, e0194924.	1.1	25
222	Aspirin Use and Respiratory Morbidity in COPD. Chest, 2019, 155, 519-527.	0.4	25
223	Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2019, 321, 1693.	3.8	25
224	Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2263-2274.e5.	2.0	25
225	Tiotropium and the Risk of Death in COPD. New England Journal of Medicine, 2014, 370, 480-483.	13.9	24
226	Gastro-oesophageal reflux and worse asthma control in obese children: a case of symptom misattribution?. Thorax, 2016, 71, 238-246.	2.7	24
227	Fluctuation Analysis of Peak Expiratory Flow and Its Association with Treatment Failure in Asthma. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 993-999.	2.5	24
228	The effect of exacerbation history on outcomes in the IMPACT trial. European Respiratory Journal, 2020, 55, 1901921.	3.1	24
229	Changes in Arterial Oxygenation and Self-Reported Oxygen Use after Lung Volume Reduction Surgery. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 339-345.	2.5	23
230	A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. BMC Public Health, 2014, 14, 761.	1.2	23
231	Asthma and Allergic Disorders in Uganda: A Population-Based Study Across Urban and Rural Settings. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1580-1587.e2.	2.0	23
232	Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis and Rheumatism, 2007, 56, 4195-4202.	6.7	22
233	Neonatal Hyperoxia Contributes Additively to Cigarette Smoke–Induced Chronic Obstructive Pulmonary Disease Changes in Adult Mice. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 610-616.	1.4	22
234	The relationship betweenHelicobacter pyloriseropositivity and COPD. Thorax, 2015, 70, 923-929.	2.7	22

#	Article	IF	CITATIONS
235	Urbanization and Daily Exposure to Biomass Fuel Smoke Both Contribute to Chronic Bronchitis Risk in a Population with Low Prevalence of Daily Tobacco Smoking. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 186-195.	0.7	22
236	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 177-185.	0.5	22
237	Primary Pulmonary Hypertension Is Not Associated With Scleroderma-Like Changes in Nailfold Capillaries. Chest, 2001, 120, 796-800.	0.4	21
238	The C523AÎ ² 2Adrenergic Receptor Polymorphism Associates with Markers of Asthma Severity in African Americans. Journal of Asthma, 2006, 43, 185-191.	0.9	21
239	Chronic Obstructive Pulmonary Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S154-S160.	1.5	21
240	Investigation of the Obesity Paradox in Chronic Obstructive Pulmonary Disease, According to Smoking Status, in the United States. American Journal of Epidemiology, 2019, 188, 1977-1983.	1.6	21
241	Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. Journal of Psychosomatic Research, 2019, 118, 18-26.	1.2	21
242	Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 297-305.	0.7	21
243	Metformin use and respiratory outcomes in asthma-COPD overlap. Respiratory Research, 2021, 22, 70.	1.4	21
244	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 313-323.	2.5	21
245	Interpretation of Pulmonary Function Test: Issues and Controversies. Clinical Reviews in Allergy and Immunology, 2009, 37, 173-180.	2.9	20
246	Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 398-404.	2.5	20
247	Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1465-1474.	2.5	20
248	Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respiratory Research, 2018, 19, 20.	1.4	20
249	A Cross Sectional Analysis of the Role of the Antimicrobial Peptide Cathelicidin in Lung Function Impairment within the ALIVE Cohort. PLoS ONE, 2014, 9, e95099.	1.1	20
250	Optimizing Treatment of Chronic Obstructive Pulmonary Disease: An Assessment of Current Therapies. American Journal of Medicine, 2007, 120, S4-S13.	0.6	19
251	Preventing Chronic Obstructive Pulmonary Disease: What Is Known and What Needs to Be Done to Make a Difference to the Patient?. American Journal of Medicine, 2007, 120, S14-S22.	0.6	19
252	Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. Annals of the Rheumatic Diseases, 2013, 72, 1136-1140.	0.5	19

#	Article	IF	CITATIONS
253	The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes. Respiratory Research, 2015, 16, 107.	1.4	19
254	Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 633-643.e1.	2.0	19
255	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society, 2021, 18, 788-798.	1.5	19
256	Clinical Phenotypes of Atopy and Asthma in COPD. Chest, 2020, 158, 2333-2345.	0.4	19
257	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. BMC Pulmonary Medicine, 2016, 16, 65.	0.8	18
258	Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25–75/FVC) in COPD. BMJ Open Respiratory Research, 2017, 4, e000231.	1.2	18
259	Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR [®] trial. International Journal of COPD, 2018, Volume 13, 605-616.	0.9	18
260	Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD. European Respiratory Journal, 2019, 54, 1900088.	3.1	18
261	Older age and obesity are associated with increased airway closure in response to methacholine in patients with asthma. Respirology, 2019, 24, 638-645.	1.3	18
262	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. Annals of the American Thoracic Society, 2022, 19, 204-213.	1.5	18
263	Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulmonary Pharmacology and Therapeutics, 2008, 21, 630-636.	1.1	17
264	Multimorbidity at sea level and high-altitude urban and rural settings: The CRONICAS Cohort Study. Journal of Comorbidity, 2019, 9, 2235042X1987529.	3.9	17
265	Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. Annals of Allergy, Asthma and Immunology, 2014, 112, 354-360.e1.	0.5	16
266	Older Adults with Chronic Lung Disease Report Less Limitation Compared with Younger Adults with Similar Lung Function Impairment. Annals of the American Thoracic Society, 2015, 12, 21-26.	1.5	16
267	Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome. Immunology and Allergy Clinics of North America, 2016, 36, 515-528.	0.7	16
268	The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants. Annals of the American Thoracic Society, 2018, 15, 200-208.	1.5	16
269	Environmental exposures and systemic hypertension are risk factors for decline in lung function. Thorax, 2018, 73, 1120-1127.	2.7	16
270	Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. Respiratory Research, 2019, 20, 190.	1.4	16

#	Article	IF	CITATIONS
271	Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. Respiratory Research, 2019, 20, 86.	1.4	16
272	Factors Associated with Persistence of Severe Asthma from Late Adolescence to Early Adulthood. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 776-787.	2.5	16
273	An Online Weight Loss Intervention for People With Obesity and Poorly Controlled Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1577-1586.e3.	2.0	16
274	Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 225-232.	2.5	15
275	Measures of asthma control. Current Opinion in Pulmonary Medicine, 2012, 18, 48-56.	1.2	15
276	Characteristics of Alpha-1 Antitrypsin–Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2015, 12, 1796-1804.	1.5	15
277	Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. International Journal of COPD, 2018, Volume 13, 1297-1308.	0.9	15
278	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. ERJ Open Research, 2021, 7, 00902-2020.	1.1	15
279	Depressive and anxiety symptoms in patients with COPD: A network analysis. Respiratory Medicine, 2022, 198, 106865.	1.3	15
280	Spirometer Calibration Checks. Chest, 2007, 131, 1486-1493.	0.4	14
281	Pharmacokinetics and Metabolism of Allâ€ <i>trans</i> end 13â€ <i>cis</i> â€Retinoic Acid in Pulmonary Emphysema Patients. Journal of Clinical Pharmacology, 2008, 48, 96-107.	1.0	14
282	Exhaled Breath Condensate pH Does Not Discriminate Asymptomatic Gastroesophageal Reflux or the Response to Lansoprazole Treatment in Children with Poorly Controlled Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 579-586.e7.	2.0	14
283	Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. Npj Primary Care Respiratory Medicine, 2015, 25, 15067.	1.1	14
284	Menthol cigarette smoking in the <scp>COPDG</scp> ene cohort: Relationship with <scp>COPD</scp> , comorbidities and <scp>CT</scp> metrics. Respirology, 2015, 20, 108-114.	1.3	14
285	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016, 71, 411-420.	2.7	14
286	RESPIRATORY PHYSIOLOGIC CHANGES IN PREGNANCY. Immunology and Allergy Clinics of North America, 2000, 20, 663-672.	0.7	13
287	Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. Clinical Trials, 2004 , 1 , $326-338$.	0.7	13
288	Notice of Retraction. Aboumatar et al. Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. JAMA. 2018;320(22):2335-2343 JAMA - Journal of the American Medical Association, 2019, 322, 1417.	3.8	13

#	Article	IF	Citations
289	The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2013, 8, e61315.	1.1	13
290	National priorities for perioperative research in South Africa. South African Medical Journal, 2016, 106, 485.	0.2	12
291	Validation of the maximum symptom day among children with asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 803-805.e10.	1.5	12
292	Does Obesity Increase Respiratory Tract Infections in Patients with Asthma?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 954-961.e6.	2.0	12
293	<p>A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings</p> . International Journal of COPD, 2020, Volume 15, 2769-2777.	0.9	12
294	Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 838-845.	2.5	12
295	Implementation of a COPD Screening Questionnaire in an Outpatient HIV Clinic. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 767-772.	0.7	11
296	HIV Infection Is Independently Associated with Increased CT Scan Lung Density. Academic Radiology, 2017, 24, 137-145.	1.3	11
297	Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary disease. ERJ Open Research, 2018, 4, 00069-2018.	1.1	11
298	Plasma cathelicidin and longitudinal lung function in current and former smokers. PLoS ONE, 2019, 14, e0212628.	1.1	11
299	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33.	2.5	11
300	Post resuscitative and initial utility in life saving efforts (pulse). Resuscitation, 2001, 50, 23-25.	1.3	10
301	Risk Factors for Montelukast Treatment Failure in Step-Down Therapy for Controlled Asthma. Journal of Asthma, 2011, 48, 1051-1057.	0.9	10
302	Hepatitis C Virus Infection Is Not An Independent Risk Factor For Obstructive Lung Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 10-16.	0.7	10
303	Validation of the Saint George's Respiratory Questionnaire in Uganda. BMJ Open Respiratory Research, 2018, 5, e000276.	1.2	10
304	Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease. Open Rheumatology Journal, 2011, 5, 1-6.	0.1	10
305	The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. American Journal of Medicine, 2022, 135, 302-312.	0.6	10
306	Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users. American Journal of Medicine, 1997, 102, 232-238.	0.6	9

#	Article	IF	Citations
307	A thermal vascular test for distinguishing between patients with Raynaud's Phenomenon and healthy controls Health Psychology, 1999, 18, 421-426.	1.3	9
308	Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. Journal of Allergy and Clinical Immunology, 2008, 122, 781-787.e8.	1.5	9
309	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respiratory Medicine, 2016, 111, 30-38.	1.3	9
310	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy, 2020, 37, 3775-3790.	1.3	9
311	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research, 2020, 21, 139.	1.4	9
312	Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. Expert Review of Respiratory Medicine, 2021, 15, 153-159.	1.0	9
313	InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respiratory Research, 2021, 22, 130.	1.4	9
314	Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort. Chest, 2021, 160, 1245-1254.	0.4	9
315	Indoor Environmental Factors May Modify the Response to Mouse Allergen Reduction Among Mouse-Sensitized and Exposed Children with Persistent Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4402-4409.e2.	2.0	9
316	Respiratory Physiology in Pregnancy. , 2009, , 19-26.		9
317	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 7-20.	0.5	9
318	Absence of positional change in pulmonary diffusing capacity in systemic sclerosis. American Journal of Medicine, 1983, 75, 305-312.	0.6	8
319	Forced expiratory capnography and chronic obstructive pulmonary disease (COPD). Journal of Breath Research, 2013, 7, 017108.	1.5	8
320	Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open, 2015, 5, e009015.	0.8	8
321	Diagnostic accuracy of FEV1/forced vital capacity ratio z scores in asthmatic patients. Journal of Allergy and Clinical Immunology, 2015, 136, 649-653.e4.	1.5	8
322	Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude. High Altitude Medicine and Biology, 2015, 16, 162-168.	0.5	8
323	Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts, Journal of the American Medical Directors Association, 2017, 18, 1063-1068.	1.2	8
324	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. Annals of the American Thoracic Society, 2018, 15, 89-101.	1.5	8

#	Article	IF	Citations
325	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. Chest, 2020, 158, 529-538.	0.4	8
326	The influence of social support on COPD outcomes mediated by depression. PLoS ONE, 2021, 16, e0245478.	1.1	8
327	Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 2021, 30, 210124.	3.0	8
328	Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax, 2022, 77, 1088-1097.	2.7	8
329	Long-Term Intersession Variability for Single-Breath Diffusing Capacity. Respiration, 2012, 84, 377-384.	1.2	7
330	Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European Respiratory Journal, 2019, 54, 1900634.	3.1	7
331	Do Baseline Asthma and Allergic Sensitization Characteristics Predict Responsiveness to Mouse Allergen Reduction?. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 596-602.e3.	2.0	7
332	Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 219-226.	0.9	7
333	Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3474-3481.	2.0	7
334	Methodology and baseline characteristics of a randomized controlled trial testing a health care professional and peer-support program for patients with chronic obstructive pulmonary disease: The BREATHE2 study. Contemporary Clinical Trials, 2020, 94, 106023.	0.8	7
335	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research, 2021, 7, 00663-2020.	1.1	7
336	"lt is kind of like a responsibility thing― transitional challenges in asthma medication adherence among adolescents and young adults. Journal of Asthma, 2022, 59, 956-966.	0.9	7
337	Comparative Impact of Depressive Symptoms and FEV ₁ % on Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19, 171-178.	1.5	7
338	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 5-15.	0.5	7
339	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 97.	1.4	7
340	Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease. Respiratory Medicine, 2010, 104, 1943-1950.	1.3	6
341	Influence of Maternal Asthma and Asthma Severity on Newborn Morphometry. Journal of Asthma, 2010, 47, 145-149.	0.9	6
342	A new measure to assess asthma's effect on quality of life from the patient's perspective. Journal of Allergy and Clinical Immunology, 2018, 141, 1085-1095.	1.5	6

#	Article	lF	Citations
343	Validity of the Asthma Control Test Questionnaire Among Smoking Asthmatics. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 151-158.	2.0	6
344	Obstructive Sleep Apnea and Airway Dimensions in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2020, 17, 116-118.	1.5	6
345	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. Chest, 2021, 159, 985-995.	0.4	6
346	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 2021, 7, 101-118.	1.1	6
347	Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease. ERJ Open Research, 2021, 7, 00068-2021.	1.1	6
348	Clinically Significant and Comorbid Anxiety and Depression Symptoms Predict Severe Respiratory Exacerbations in Smokers: A <i>Post Hoc</i> Analysis of the COPDGene and SPIROMICS Cohorts. Annals of the American Thoracic Society, 2022, 19, 143-146.	1.5	6
349	Home Dust Allergen Exposure Is Associated with Outcomes among Sensitized Individuals with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 412-420.	2.5	6
350	Evaluating construct validity of the Asthma Impairment and Risk Questionnaire using a 3-month exacerbation recall. Annals of Allergy, Asthma and Immunology, 2022, 128, 544-552.e3.	0.5	6
351	Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics. Contemporary Clinical Trials, 2002, 23, 87-92.	2.0	5
352	Oxygen Therapy in COPD: What Do We Know?. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 321-322.	2.5	5
353	Ethical Issues Confronted In Pulmonary Clinical Trials. Proceedings of the American Thoracic Society, 2007, 4, 200-205.	3.5	5
354	The Role of NETT in Emphysema Research. Proceedings of the American Thoracic Society, 2008, 5, 385-392.	3.5	5
355	Discordance in investigator-reported and adjudicated sudden death in TIOSPIR. ERJ Open Research, 2017, 3, 00073-2016.	1.1	5
356	Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing. Pulmonary Pharmacology and Therapeutics, 2018, 53, 27-32.	1.1	5
357	Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME). Contemporary Clinical Trials Communications, 2020, 18, 100427.	0.5	5
358	High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq0 ()	Ov e rlock 10 Ti
359	Recruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons Learned. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 265-278.	0.5	5
360	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 370-381.	0.5	5

#	Article	IF	CITATIONS
361	Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial. International Journal of COPD, 2016, 11, 133.	0.9	4
362	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respiratory Medicine, 2016, 120, 91-100.	1.3	4
363	Reproducibility of airway luminal size in asthma measured by HRCT. Journal of Applied Physiology, 2017, 123, 876-883.	1.2	4
364	Lung Cancer–Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results. Diabetes Care, 2019, 42, 1708-1715.	4. 3	4
365	Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD. ERJ Open Research, 2020, 6, 00177-2019.	1.1	4
366	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 2021, 22, 213.	0.7	4
367	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 2021, 58, 2004522.	3.1	4
368	Losartan Effects on Emphysema Progression Randomized Clinical Trial: Rationale, Design, Recruitment, and Retention. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 414-426.	0.5	4
369	A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 186-193.	0.5	4
370	Effect of urbanisation on the relationship between total serum IgE and asthma. European Respiratory Journal, 2013, 41, 1074-1081.	3.1	3
371	A cross-sectional study of differences in 6-min walk distance in healthy adults residing at high altitude versus sea level. Extreme Physiology and Medicine, 2014, 3, 3.	2.5	3
372	Tiotropium safety in â€realâ€world' populations. British Journal of Clinical Pharmacology, 2016, 82, 562-563.	1.1	3
373	Long-Term Oxygen for COPD. New England Journal of Medicine, 2017, 376, 286-287.	13.9	3
374	Effect of intranasal corticosteroids on allergic airway disease in asthma. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1125-1128.e3.	2.0	3
375	Patterns of Body Composition Relating to Chronic Respiratory Diseases Among Adults in Four Resource-Poor Settings in Peru. Lung, 2018, 196, 277-284.	1.4	3
376	Medication Regimens for Managing COPD Exacerbations. Respiratory Care, 2018, 63, 773-782.	0.8	3
377	Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma. Rheumatology, 2020, 59, 790-798.	0.9	3
378	Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Review of Respiratory Medicine, 2021, 15, 1093-1106.	1.0	3

#	Article	IF	Citations
379	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. Journal of Clinical Investigation, 2014, 124, 5521-5521.	3.9	3
380	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 210-220.	0.5	3
381	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, , .	0.5	3
382	Pulmonary Rehabilitation and Clinical Trial Design in Patients with Severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 305-309.	0.7	2
383	Exposure to neonatal cigarette smoke causes durable lung changes but does not potentiate cigarette smoke $\hat{a}\in ``induced chronic obstructive pulmonary disease in adult mice. Experimental Lung Research, 2011, 37, 354-363.$	0.5	2
384	Asthma clinical trials of American Lung Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12Âyears?. Current Respiratory Care Reports, 2012, 1, 251-258.	0.6	2
385	The Tiotropium Safety and Performance in Respimat (TIOSPIR) trial: Bronchodilator efficacy in a spirometry substudy. Chest, 2013, 144, 1027A.	0.4	2
386	Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups. Journal of Allergy and Clinical Immunology, 2019, 143, 395-402.e7.	1.5	2
387	Clinical characterization of children with resistant airflow obstruction, a multicenter study. Journal of Asthma, 2019, 56, 611-617.	0.9	2
388	Self-medication as Part of Self-management Plans for Patients With COPDâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1937.	3.8	2
389	Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 371-381.	0.5	2
390	Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. Clinical Trials, 2020, 17, 430-436.	0.7	2
391	Reply: Prognostic Value of Functional Decline in Middle-Aged Smokers. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1029-1029.	2.5	1
392	Reply: A Call to Apply the Minimal Important Difference in Pulmonary Arterial Hypertension beyond the Flawed 6-Minute-Walk Test. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 659-659.	2.5	1
393	The American Lung Association: Asthma Clinical Research Centers network: addressing real life questions in asthma management. Clinical Investigation, 2014, 4, 495-499.	0.0	1
394	Caesarean section and anaesthetic mortality. Southern African Journal of Anaesthesia and Analgesia, 2015, 21, 145-145.	0.1	1
395	Identifying an at-risk population for poor asthma outcomes: Data from the American Lung Association Asthma Clinical Trials Registry. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2872-2874.	2.0	1
396	Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 277-291.	0.5	1

#	Article	IF	CITATIONS
397	Reply to LÃ ³ pez-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 928-929.	2.5	1
	InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone) Tj ETQq0 0 0	O rgBT /Ov	erlock 10 Tf
398	in Patients With COPD: Analysis of the Western Europe and North America Regions. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 76-90.	0.5	1
399	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respiratory Research, 2021, 22, 272.	1.4	1
400	The COPD Foundation Coronavirus Disease 2019 International Medical Experts Survey: Results. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 139-146.	0.5	1
401	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 473-481.	2.5	1
402	Comparing Self-Management Programs with and without Peer Support among Patients with Chronic Obstructive Pulmonary Disease: A Clinical Trial. Annals of the American Thoracic Society, 2022, 19, 1687-1696.	1.5	1
403	Confounding Issues in COPD Risk Study?. Chest, 2003, 123, 307-308.	0.4	O
404	Survey on Quality of Training in Pulmonary Physiology During Fellowship. Chest, 2007, 131, 1270-1271.	0.4	0
405	Reply. Journal of Allergy and Clinical Immunology, 2015, 136, 212-213.	1.5	0
406	Response. Chest, 2017, 151, 1397-1398.	0.4	0
407	THE AUTHORS REPLY. American Journal of Epidemiology, 2020, 189, 482-482.	1.6	0
408	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 326-335.	0.5	0
409	The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. International Journal of COPD, 2021, Volume 16, 689-699.	0.9	O
410	Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	1.3	0
411	Celebration of the 50-Year Anniversary of the National Heart, Lung, and Blood Institute Division of Lung Diseases: A Half-Century of Landmark Clinical Trials. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 359-370.	0.5	0
412	Reply to: Selecting the Right Patient: The Achilleâ \in TM s Heel of COPD Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0